If you are:
FDB Only When Necessary: INSUFFICIENT DATA AVAILABLE; NEONATE RISK OF SEIZURES;AVOID DURING 3RD TRIMESTER
Only When Necessary: ONLY AVAILABLE IN COMBINATION PRODUCTS THAT ARE ASSIGNED FDA CATEGORY C.
Only When Necessary: EVIDENCE FOR MALFORMATIONS; CAN REDUCE UTERINE BLOOD FLOW CAUSING FETAL HYPOXIA
Precaution: INSUFFICIENT DATA AVAILABLE.
Precaution: ORAL BIOAVAILABILITY LOW; INFANT EXPOSURE MAY BE MINIMAL
Precaution: INSUFFICIENT DATA AVAILABLE; MAY CAUSE SEDATION AND INHIBIT LACTATION
An adult over 60:
management or monitoring precaution: Cardiovascular-Elderly are more sensitive to tachycardia and hypertensive effects. May exacerbate symptomatic coronary insufficiency. Genitourinary-May cause urinary retention. Neuro/Psych-May worsen cognitive impairment in some elderly with dementia. Insomnia risk.
management or monitoring precaution: Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Non-sedating antihistamine preferred. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Giving chlorpheniram-pe-chlophedianol-tablet to a child under 12:
Severe Precaution: Not recommended in children under 6 years unless clinician consultation.
Contraindication: Risk of CNS effects. Not recommended age < 6 years unless clinician consult.
Contraindication: Possible paradoxical CNS excitation. Seizure risk in newborns.
Contraindication: Risk of CNS excitation. Do not use age <6 years without clinician consult.